Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Otonomy, Inc. clinical trials
The registry lists 22 studies whose lead sponsor is Otonomy, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 20, 2023.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Otonomy, Inc..
- Otonomy, Inc.22 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- A 6-Month Extension Study of OTO-104 in Meniere's DiseaseTerminatedNCT02768662Phase 3
- Study of OTO-104 in Subjects With Unilateral Meniere's DiseaseTerminatedNCT02717442Phase 3
- Study of OTO-104 in Subjects With Unilateral Meniere's DiseaseCompletedNCT02612337Phase 3
- OTO-313 in Subjects With Unilateral Subjective TinnitusCompletedNCT04829214Phase 2
- OTO-313 in Subjects With Subjective TinnitusCompletedNCT03918109Phase 1/2
- A 6-Month Extension Study of OTO-104 in Meniere's DiseaseTerminatedNCT02706730Phase 3
- Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's DiseaseCompletedNCT03664674Phase 3
- OTO-413 in Subjects With Speech-in-Noise Hearing ImpairmentCompletedNCT04129775Phase 1/2
- Open-Label Study of OTO-201 for Treatment of AOMTCompletedNCT02408796Phase 2
- Dose Ranging Study of OTO-201 in AOMTCompletedNCT02719158Phase 2
- Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy TubesCompletedNCT02600559Phase 3
- Phase 3 Study of OTO-201 in Acute Otitis ExternaCompletedNCT02801370Phase 3
- OTO-201 for the Treatment of Otitis ExternaCompletedNCT02511561Phase 2
- Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube AdministrationCompletedNCT02350998Phase 3
- Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing LossTerminatedNCT02997189Phase 2
- Open Label Study of OTO-104 in Subjects With Meniere's DiseaseTerminatedNCT02740387Phase 2
- A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United KingdomCompletedNCT02265393Phase 2
- OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube PlacementCompletedNCT01949155Phase 3
- OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube PlacementCompletedNCT01949142Phase 3
- OTO-104 for the Treatment of Meniere's DiseaseCompletedNCT01412177Phase 2
- OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube PlacementCompletedNCT01755286Phase 1
- OTO-104 for Meniere's DiseaseCompletedNCT01084525Phase 1